245 Summer Street,
Boston , MA, 02210

Rank

Rank Universe
25 60

Summary

The fund seeks capital appreciation by investing in companies in the United States.

The investment process is designed to highlight companies that are engaged in the design, manufacture, or sale of products or services used for or in connection with health care or medicine.

Next, the research team evaluates a company’s financial condition and industry position, as well as market and economic conditions.

Then More

Link

Directors

Oct 13, 2023
  • OSCAR MUNOZ
  • ROBERT A LAWRENCE
  • THOMAS A KENNEDY
  • BETTINA DOULTON
  • VICKI L FULLER
  • THOMAS P BOSTICK
  • PATRICIA L KAMPLING
  • DENNIS J DIRKS
  • DONALD F DONAHUE
  • MICHAEL E WILEY
  • SUSAN TOMASKY
  • DAVID M THOMAS
  • VIJAY ADVANI

Chief Compliance Officer

  • JASON POGORELEC

Fund Manager(s)

Price

  • $ 55.86 ( +0.25 )
    Jan 2, 2025
    Last Close
  • Net Assets
  • $4.8B
    Mar 27, 2024
  • Holding
  • 104
    Sep 25, 2024
    More

  • 52-Week High/Low
  • $68.86 - $55.61
  • Turnover
  • 33%
  • Expense Ratio
  • 0.94%

Company Name

Holding

BOSTON SCIENTIFIC CORP 9.49 %
ELI LILLY and CO 8.23 %
UNITEDHEALTH GROUP INC 7.8 %
DANAHER CORP 6.37 %
REGENERON PHARMACEUTICALS INC 4.36 %
Fidelity Revere Street Trust 4.19 %
MERCK and CO INC 3.92 %
CIGNA GROUP (THE) 3.43 %
PENUMBRA INC 3.04 %
STRYKER CORP 2.34 %
More 2.34 %

Documents

Prospectus

Annual Reports

Performance

YTD

-

3 Year

-3.34%

5 Year

0.2%

Best

55.75%

2013

Worst

-33.01%

2008

Alpha

FACDX S&P 500

Chart +